EGFR and neoplasm: Quiescent G12Ci resistant tumor cells are able to reactivate KRAS signaling and resume proliferation by increasing the synthesis of active KRAS-GTP or stimulating upstream regulators such as EGFR, SHP2 and AURKA 158.